Nucleic acid sequence-based amplification assay for human papillomavirus mRNA detection and typing: Evidence for DNA amplification

Journal of Clinical Microbiology

Volumn 48, Issue 7, 2010, Pages 2524-2529

  Boulet, Gaëlle A V ^a   Micalessi, Isabel M ^a   Horvath, Caroline A J ^a   Benoy, Ina H ^b   Depuydt, Christophe E ^b   Bogers, Johannes J ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Laboratory for Clinical Pathology (Labo Lokeren Campus RIATOL)   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; VIRUS DNA; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; NONHUMAN; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PRIORITY JOURNAL; VIRUS DETECTION; WART VIRUS; ALPHAPAPILLOMAVIRUS; CLASSIFICATION; GENETICS; HELA CELL LINE; ISOLATION AND PURIFICATION; NUCLEIC ACID AMPLIFICATION; PAPILLOMAVIRUS INFECTION; PLASMID; PROCEDURES; REPRODUCIBILITY; TUMOR CELL LINE; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

ALPHAPAPILLOMAVIRUS; CELL LINE, TUMOR; DNA, VIRAL; HELA CELLS; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PAPILLOMAVIRUS INFECTIONS; PLASMIDS; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; VIROLOGY;

EID: 77954454261     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00173-10     Document Type: Article

References (41)

1. Arbyn, M., F. Buntinx, M. Van Ranst, E. Paraskevaidis, P. Martin-Hirsch, and J. Dillner. 2004. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J. Natl. Cancer Inst. 96:280-293.
2. Arbyn, M., E. Paraskevaidis, P. Martin-Hirsch, W. Prendiville, and J. Dillner. 2005. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol. Oncol. 99:S7-S11.
3. Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study Group. 2000. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J. Natl. Cancer Inst. 92:397-402.
4. Bosch, F. X., A. Lorincz, N. Munoz, C. J. Meijer, and K. V. Shah. 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55:244-265.
5. Boulet, G. A., C. A. Horvath, S. Berghmans, and J. Bogers. 2008. Human papillomavirus in cervical cancer screening: important role as biomarker. Cancer Epidemiol. Biomarkers Prev. 17:810-817.
6. Cattani, P., A. Siddu, S. D'Onghia, S. Marchetti, R. Santangelo, V. G. Vellone, G. F. Zannoni, and G. Fadda. 2009. RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus. J. Clin. Microbiol. 47:2136-2141.
7. Cattani, P., G. F. Zannoni, C. Ricci, S. D'Onghia, I. N. Trivellizzi, A. Di Franco, V. G. Vellone, M. Durante, G. Fadda, G. Scambia, G. Capelli, and R. De Vincenzo. 2009. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J. Clin. Microbiol. 47:3895-3901.
8. Clifford, G., S. Franceschi, M. Diaz, N. Munoz, and L. L. Villa. 2006. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24(Suppl. 3):S3/26-S3/34.
9. Cuschieri, K., and N. Wentzensen. 2008. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev. 17:2536-2545.
10. Cuschieri, K. S., M. J. Whitley, and H. A. Cubie. 2004. Human papillomavirus type specific DNA and RNA persistence - implications for cervical disease progression and monitoring. J. Med. Virol. 73:65-70.
11. Cuzick, J., M. Arbyn, R. Sankaranarayanan, V. Tsu, G. Ronco, M. H. Mayrand, J. Dillner, and C. J. Meijer. 2008. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26(Suppl. 10):K29-K41.
12. Deiman, B., P. van Aarle, and P. Sillekens. 2002. Characteristics and applications of nucleic acid sequence-based amplification (NASBA). Mol. Biotechnol. 20:163-179.
13. Depuydt, C. E., I. H. Benoy, E. J. Bailleul, J. Vandepitte, A. J. Vereecken, and J. J. Bogers. 2006. Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi. Cytopathology 17:374-381.
14. Depuydt, C. E., G. A. Boulet, C. A. Horvath, I. H. Benoy, A. J. Vereecken, and J. J. Bogers. 2007. Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J. Cell Mol. Med. 11:881-891.
15. Gravitt, P. E., F. Coutlee, T. Iftner, J. W. Sellors, W. G. Quint, and C. M. Wheeler. 2008. New technologies in cervical cancer screening. Vaccine 26(Suppl. 10):K42-K52.
16. Horvath, C. A., G. Boulet, S. Sahebali, C. Depuydt, T. Vermeulen, D. Vanden Broeck, A. Vereecken, and J. Bogers. 2008. Effects of fixation on RNA integrity in a liquid-based cervical cytology setting. J. Clin. Pathol. 61:132-137.
17. Jeantet, D., F. Schwarzmann, J. Tromp, W. J. Melchers, A. A. van der Wurff, T. Oosterlaken, M. Jacobs, and A. Troesch. 2009. NucliSENS EasyQ HPV v1 test - testing for oncogenic activity of human papillomaviruses. J. Clin. Virol. 45(Suppl. 1):S29-S37.
18. Keegan, H., J. McInerney, L. Pilkington, P. Gronn, I. Silva, F. Karlsen, N. Bolger, C. Logan, L. Furuberg, J. O'Leary, and C. Martin. 2009. Comparison of HPV detection technologies: hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J. Virol. Methods 155:61-66.
19. Kraus, I., T. Molden, R. Holm, A. K. Lie, F. Karlsen, G. B. Kristensen, and H. Skomedal. 2006. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J. Clin. Microbiol. 44:1310-1317.
20. Lie, A. K., B. Risberg, B. Borge, B. Sandstad, J. Delabie, R. Rimala, M. Onsrud, and S. Thoresen. 2005. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol. Oncol. 97:908-915.
21. Middleton, K., W. Peh, S. Southern, H. Griffin, K. Sotlar, T. Nakahara, A. El-Sherif, L. Morris, R. Seth, M. Hibma, D. Jenkins, P. Lambert, N. Coleman, and J. Doorbar. 2003. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J. Virol. 77:10186-10201.
22. Molden, T., I. Kraus, F. Karlsen, H. Skomedal, J. F. Nygard, and B. Hagmar. 2005. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol. Biomarkers Prev. 14:367-372.
23. Molden, T., I. Kraus, H. Skomedal, T. Nordstrom, and F. Karlsen. 2007. PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J. Virol. Methods 142:204-212. (Pubitemid 46590424)
24. Molden, T., J. F. Nygard, I. Kraus, F. Karlsen, M. Nygard, G. B. Skare, H. Skomedal, S. O. Thoresen, and B. Hagmar. 2005. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int. J. Cancer 114:973-976.
25. Nakagawa, S., H. Yoshikawa, T. Yasugi, M. Kimura, K. Kawana, K. Matsumoto, M. Yamada, T. Onda, and Y. Taketani. 2000. Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. J. Med. Virol. 62:251-258.
26. Naucler, P., W. Ryd, S. Tornberg, A. Strand, G. Wadell, K. Elfgren, T. Radberg, B. Strander, B. Johansson, O. Forslund, B. G. Hansson, E. Rylander, and J. Dillner. 2007. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357:1589-1597.
27. Paraskevaidis, E., M. Arbyn, A. Sotiriadis, E. Diakomanolis, P. Martin-Hirsch, G. Koliopoulos, G. Makrydimas, J. Tofoski, and D. H. Roukos. 2004. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat. Rev. 30:205-211.
28. Powell, N., K. Smith, and A. Fiander. 2006. Recovery of human papillomavirus nucleic acids from liquid-based cytology media. J. Virol. Methods 137:58-62. (Pubitemid 44189506)
29. Rodriguez-Lazaro, D., J. Lloyd, J. Ikonomopoulos, M. Pla, and N. Cook. 2004. Unexpected detection of DNA by nucleic acid sequence-based amplification technique. Mol. Cell Probes 18:251-253.
30. Ronco, G., S. Brezzi, F. Carozzi, P. P. Dalla, P. Giorgi-Rossi, D. Minucci, C. Naldoni, N. Segnan, M. Zappa, M. Zorzi, and J. Cuzick. 2007. The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. Gynecol. Oncol. 107:S230-S232.
31. Rose, B. R., C. H. Thompson, M. H. Tattersall, P. M. Elliott, C. Dalrymple, and Y. E. Cossart. 1995. Identification of E6/E7 transcription patterns in HPV 16-positive cervical cancers using the reverse transcription/polymerase chain reaction. Gynecol. Oncol. 56:239-244.
32. Sotlar, K., A. Stubner, D. Diemer, S. Menton, M. Menton, K. Dietz, D. Wallwiener, R. Kandolf, and B. Bultmann. 2004. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J. Med. Virol. 74:107-116.
33. Stanley, M., L. Gissmann, and D. Nardelli-Haefliger. 2008. Immunobiology of human papillomavirus infection and vaccination-implications for second generation vaccines. Vaccine 26(Suppl. 10):K62-K67.
34. Steinau, M., M. S. Rajeevan, and E. R. Unger. 2006. DNA and RNA references for qRT-PCR assays in exfoliated cervical cells. J. Mol. Diagn. 8:113-118.
35. Szarewski, A., L. Ambroisine, L. Cadman, J. Austin, L. Ho, G. Terry, S. Liddle, R. Dina, J. McCarthy, H. Buckley, C. Bergeron, P. Soutter, D. Lyons, and J. Cuzick. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev. 17:3033-3042.
36. Trope, A., K. Sjoborg, A. Eskild, K. Cuschieri, T. Eriksen, S. Thoresen, M. Steinbakk, V. Laurak, C. M. Jonassen, U. Westerhagen, M. B. Jacobsen, and A. K. Lie. 2009. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J. Clin. Microbiol. 47:2458-2464.
37. Vernon, S. D., E. R. Unger, and D. Williams. 2000. Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J. Clin. Microbiol. 38:651-655.
38. Voisset, C., B. Mandrand, and G. Paranhos-Baccala. 2000. RNA amplification technique, NASBA, also amplifies homologous plasmid DNA in non-denaturing conditions. Biotechniques 29:236-238, 240.
39. Wang-Johanning, F., D. W. Lu, Y. Wang, M. R. Johnson, and G. L. Johanning. 2002. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 94:2199-2210.
40. Yates, S., M. Penning, J. Goudsmit, I. Frantzen, B. van de Weijer, D. van Strijp, and B. van Gemen. 2001. Quantitative detection of hepatitis B virus DNA by real-time nucleic acid sequence-based amplification with molecular beacon detection. J. Clin. Microbiol. 39:3656-3665.
41. Zielinski, G. D., A. G. Bais, T. J. Helmerhorst, R. H. Verheijen, F. A. de Schipper, P. J. Snijders, F. J. Voorhorst, F. J. van Kemenade, L. Rozendaal, and C. J. Meijer. 2004. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet. Gynecol. Surv. 59:543-553.